La vendita allo scoperto per Above Food Ingredients dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Above Food Ingredients. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Above Food Ingredients (NASDAQ:ABVE) Azioni, Report sulle vendite allo scoperto

Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.

Above Food Ingredients

Above Food Ingredients Inc. - Common Stock

Above Food Ingredients Inc

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and raises the price target from $55 to $57.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Raises Price Target to $57

Truist Securities analyst Brian Foran maintains UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Buy and raises the price target from $120 to $128.

UMBF

Truist Securities Maintains Buy on UMB Financial, Raises Price Target to $128

GLBKV

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

GLBAV

Trading Halt: Halt status updated at 9:40:02 AM ET: Quotation Resumption: New Issue Available

Wells Fargo analyst Michael Brown maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $153 to $167.

Wells Fargo Maintains Equal-Weight on Blackstone, Raises Price Target to $167

Wells Fargo analyst Michael Brown maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and raises the price target from $189 to $202.

ARES

Wells Fargo Maintains Overweight on Ares Management, Raises Price Target to $202

Wells Fargo analyst Michael Brown maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $160 to $173.

Wells Fargo Maintains Overweight on Apollo Asset Management, Raises Price Target to $173

Milestone&#xAE; Pharmaceuticals Inc. ("Milestone") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the "Offering") of (i) 31,500,000 of its common shares (the "Shares"), accompanying Series A common warrants (the "Series A Common Warrants") to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the "Series B Common Warrants") to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.
Milestone intends to use the net proceeds from the Offering together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT), as well as for working capital and other general corporate purposes.

MIST

Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025

Wells Fargo analyst Ike Boruchow maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Overweight and raises the price target from $22 to $25.

LEVI

Wells Fargo Maintains Overweight on Levi Strauss, Raises Price Target to $25

<a href="https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2" title="https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2">https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2</a>

'Delta Strips Engines Off New Airbus Jets To Overcome US Shortage' - Bloomberg

United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) and Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) report that the US Department of Justice Antitrust Division announced yesterday that it has closed its investigation into the proposed transaction with T-Mobile. The transaction remains subject to approval by the Federal Communications Commission (FCC), and we continue to work with the FCC as they complete their independent assessment.

United States Cellular And Telephone And Data Systems Say US Department Of Justice Antitrust Division Closes Investigation Into Proposed Transaction With T-Mobile

Truist Securities analyst David Smith maintains Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Buy and raises the price target from $56 to $60.

Truist Securities Maintains Buy on Synovus Financial, Raises Price Target to $60

Wells Fargo analyst Stephen Baxter downgrades Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) from Equal-Weight to Underweight and lowers the price target from $16 to $10.

Downgrades

OSCR

Wells Fargo Downgrades Oscar Health to Underweight, Lowers Price Target to $10

Truist Securities analyst Brandon King maintains Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Buy and raises the price target from $123 to $127.

PNFP

Truist Securities Maintains Buy on Pinnacle Finl Partners, Raises Price Target to $127

UBS analyst Joshua Spector downgrades Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) from Neutral to Sell and lowers the price target from $64 to $57.

UBS Downgrades Albemarle to Sell, Lowers Price Target to $57

Truist Securities analyst Brian Foran maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Buy and raises the price target from $26 to $27.

Truist Securities Maintains Buy on Old National, Raises Price Target to $27

General

ALTI

AlTi Global To Wind Down Non-Core International Real Estate Business

Truist Securities analyst David Smith maintains F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) with a Buy and raises the price target from $16.5 to $17.5.

Truist Securities Maintains Buy on F N B, Raises Price Target to $17.5

<a href="https://www.reuters.com/sustainability/boards-policy-regulation/meta-wont-tweak-pay-or-consent-model-further-despite-risk-eu-fines-sources-say-2025-07-11/" title="https://www.reuters.com/sustainability/boards-policy-regulation/meta-wont-tweak-pay-or-consent-model-further-despite-risk-eu-fines-sources-say-2025-07-11/">https://www.reuters.com/sustainability/boards-policy-regulation/meta-wont-tweak-pay-or-consent-model-further-despite-risk-eu-fines-sources-say-2025-07-11/</a>

Government

Regulations

'Meta Won't Tweak Pay-Or-Consent Model Further Despite Risk Of EU Fines, Sources Say' - Reuters

UBS analyst Michael Ward upgrades Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) from Sell to Neutral and raises the price target from $28 to $37.

Upgrades

CRBG

UBS Upgrades Corebridge Financial to Neutral, Raises Price Target to $37

Press Releases

Private Placement to Accelerate Growth and Enhance Profitability

Reporting Requirements

Above Food Ingredients Inc. Files Interim Financial Statements

Above Food Ingredients Inc. Files Financial Results for the Six-Month Period Ended July 31, 2024

Above Food Ingredients Inc. and Palm Global Technologies Advance Strategic Merger with Definitive Agreements Expected to be Signed Imminently

Palm Global Partners with Abu Dhabi's Promax United to Transform Global Finance, Creating the World's Largest Portfolio of Real-World Asset-Backed Investment Products, Fixed-Income Funds, and Stablecoins

Comments

Above Food Ingredients

Vendite allo scoperto

Above Food Ingredients (NASDAQ:ABVE) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO